Skip to main content

Peer Review reports

From: Real-world experience of first-line afatinib in patients with EGFR -mutant advanced NSCLC: a multicenter observational study

Original Submission
2 Apr 2019 Submitted Original manuscript
5 Aug 2019 Author responded Author comments - Gwo Fuang Ho
5 May 2019 Reviewed Reviewer Report - Alessandro Morabito
11 Jul 2019 Reviewed Reviewer Report - Wa Xian
Resubmission - Version 2
5 Aug 2019 Submitted Manuscript version 2
25 Aug 2019 Author responded Author comments - Gwo Fuang Ho
10 Aug 2019 Reviewed Reviewer Report - Alessandro Morabito
7 Aug 2019 Reviewed Reviewer Report - Wa Xian
Resubmission - Version 3
25 Aug 2019 Submitted Manuscript version 3
28 Aug 2019 Author responded Author comments - Gwo Fuang Ho
26 Aug 2019 Reviewed Reviewer Report - Alessandro Morabito
Resubmission - Version 4
28 Aug 2019 Submitted Manuscript version 4
Publishing
29 Aug 2019 Editorially accepted
9 Sep 2019 Article published 10.1186/s12885-019-6107-1

You can find further information about peer review here.

Back to article page